Modulating CD27 signaling to treat cancer
| Data(s) |
2012
|
|---|---|
| Resumo |
CD27 signaling can either improve T-cell function or lead to T-cell dysfunction, depending on the duration and conditions of receptor ligation. Recent studies have shown that modulating the CD70-CD27 interaction is an attractive strategy to treat solid tumors and also to directly target leukemia stem cells. |
| Formato |
application/pdf |
| Identificador |
http://boris.unibe.ch/12776/1/onci%252E21425.pdf Riether, Carsten; Schürch, Christian; Ochsenbein, Adrian (2012). Modulating CD27 signaling to treat cancer. Oncoimmunology, 1(9), pp. 1604-1606. Austin, Tex.: Landes Bioscience 10.4161/onci.21425 <http://dx.doi.org/10.4161/onci.21425> doi:10.7892/boris.12776 info:doi:10.4161/onci.21425 info:pmid:23264908 urn:issn:2162-4011 |
| Idioma(s) |
eng |
| Publicador |
Landes Bioscience |
| Relação |
http://boris.unibe.ch/12776/ |
| Direitos |
info:eu-repo/semantics/restrictedAccess |
| Fonte |
Riether, Carsten; Schürch, Christian; Ochsenbein, Adrian (2012). Modulating CD27 signaling to treat cancer. Oncoimmunology, 1(9), pp. 1604-1606. Austin, Tex.: Landes Bioscience 10.4161/onci.21425 <http://dx.doi.org/10.4161/onci.21425> |
| Palavras-Chave | #610 Medicine & health |
| Tipo |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion PeerReviewed |
